Author
Stock Market LIVE Updates | Alembic Pharmaceuticals receives USFDA nod for Carbamazepine tablets
The company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine extended-release tablets.
These tablets are used as an anticonvulsant drug and for the treatment of pain associated with true trigeminal neuralgia. Carbamazepine had an estimated market size of $71 million for the twelve months ending March 2025, according to IQVIA.
Alembic Pharmaceuticals was quoting at Rs 1,007.10, up Rs 8.80, or 0.88 percent.
It has touched an intraday high of Rs 1,024.70 and an intraday low of Rs 998.15.
It was trading with volumes of 2,095 shares, compared to its five day average of 3,806 shares, a decrease of -44.95 percent.
In the previous trading session, the share closed down 1.96 percent or Rs 20.00 at Rs 998.30.
The share touched a 52-week high of Rs 1,296.15 and a 52-week low of Rs 725.60 on 09 October, 2024 and 03 March, 2025, respectively.
Currently, the stock is trading 22.3 percent below its 52-week high and 38.8 percent above its 52-week low.
Market capitalisation stands at Rs 19,795.87 crore.
